The primary focus of our research is to disrupt protein-protein interactions (PPIs) involving challenging oncology targets such as MYC, which is overexpressed in over 70% of cancers. Grove is targeting the MYC interaction network, pursuing multiple PPI entry points in parallel. In addition, our platform-validating KEAP1/NRF2 program has potential application in neurodegenerative disease and other conditions linked to oxidative stress.